ASCLETIS-B (01672.HK): ASC30_48 FDC Cuts Weight 52% More Than ASC30

On 16 November 2026, ASCLETIS-B (01672.HK) said ASC30_48 FDC cut weight 10.5% versus 6.9% for ASC30 alone in monkey tests, a 52% relative improvement.

NewTimeSpace News: On 16 November 2026, Ascletis Pharma Inc. (stock code: 01672) announced that it presented key preclinical results for its oral small molecule GIPR agonist ASC48, the GLP-1R/GIPR dual-targeted oral small molecule ASC30_48 FDC (a fixed-dose combination of ASC30 and ASC48) and the long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek® 2026, held in Washington, DC from 14 to 17 November 2026.

In a randomised non-human primate study, 15 male cynomolgus monkeys were dosed orally once daily for eight days with ASC30 (2 mg/kg), ASC48 (5 mg/kg) or ASC30_48 FDC (2 mg/kg ASC30 plus 5 mg/kg ASC48). On day 9, body weight fell 10.5% in the FDC group, 6.9% with ASC30 alone and 1.7% with ASC48 alone, a relative improvement of about 52% over ASC30 monotherapy. ASC48 showed an EC50 of 1 pM in a humanised GIPR-mediated cAMP assay versus 3 pM for tirzepatide, with a half-life of 16.2 hours after eight oral doses at 5 mg/kg in cynomolgus monkeys.

ASC37, given subcutaneously at 0.5 mg/kg in non-human primates, showed an observed half-life of 372 hours (15.5 days), about 6.4 times the 57.8 hours of retatrutide; its EC50 in an in vitro insulin secretion assay was 0.9858 nM versus 23.03 nM for retatrutide, or about 23.4 times more potent. In diet-induced obese mice dosed once daily at 1, 10 and 30 nmol/kg, body weight fell 14.1%, 30.1% and 41.5% from baseline by day 12, versus 4.7% in the vehicle control. The announcement carries the Rule 18A.05 warning that development and commercialisation of these candidates are not guaranteed.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.